Ambros Therapeutics to merge with Werewolf Therapeutics in all-stock deal
What's the deal? Werewolf TherapeuticsDealroom has a profile for this one. Try Dealroom → and Ambros TherapeuticsDealroom has a profile for this one. Try Dealroom → have signed a definitive all-stock merger agreement to form a Nasdaq-listed, late-stage biotech developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The companies also secured commitments for a concurrent, oversubscribed $150 million private placement.
The combined company will operate as Ambros Therapeutics, stay headquartered in San Diego, and trade under the ticker "AMBX." The deal is expected to close by the first quarter of 2027, subject to shareholder and Nasdaq approvals.
What's the endgame? Neridronate is a bisphosphonate targeting CRPS-1, a debilitating orphan disease with roughly 65,000 new US diagnoses each year and no FDA-approved treatments. It holds Breakthrough Therapy, Fast Track, and Orphan Drug designations.
The drug, developed by Abiogen PharmaDealroom has a profile for this one. Try Dealroom →, is already approved in Italy for CRPS, osteogenesis imperfecta, and Paget's disease, where it has been given to about 600,000 patients. Ambros is running the CRPS-RISE Phase 3 trial, expected to enrol around 270 patients, with topline results anticipated in 2028.
What are the terms? The merger values Ambros at an implied $500 million before the private placement and Werewolf at an implied $47.5 million. Pre-merger Ambros shareholders will own about 71.7% of the combined company, financing investors about 21.5%, and other Werewolf shareholders roughly 6.8%.
The financing is co-led by RA Capital Management and Janus Henderson Investors, with participation from Aberdeen InvestmentsDealroom has a profile for this one. Try Dealroom →, Adage Capital PartnersDealroom has a profile for this one. Try Dealroom →, Balyasny Asset ManagementDealroom has a profile for this one. Try Dealroom →, and others. Werewolf will issue common stock and pre-funded warrants for $150 million in gross proceeds at closing, extending the cash runway into the first half of 2029.
Why now? The transaction follows a strategic review by Werewolf, a biopharma developing immune-based cancer therapies through its PREDATOR platform. Chief executive officer Daniel J. Hicklin said the board concluded the merger "represented the best option for shareholders."
What could go wrong? Ambros believes positive results from the single Phase 3 trial could support US approval, based on FDA discussions. But a one-trial approval path leaves little margin — a miss on the week-12 pain endpoint would undercut the entire thesis.
The signal: The deal is a reverse-merger route to public markets, letting a private late-stage asset gain a Nasdaq listing and fresh capital while giving Werewolf shareholders a stake plus a contingent value right on legacy assets. It reflects how struggling clinical-stage biotechs are increasingly repurposed as vehicles for better-funded pipelines.
Read more: citybiz.co
Image credit: Generated with Gemini
